Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic prophylaxis for excision-graft surgery in burn patients
2019-002396-34Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2019
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in burn injury comparing Piperacillin + tazobactam prophylaxis with Cefazolin prophylaxis (2 arms). Primary endpoint: Primary composite endpoint. Started Oct 2019; status: active.
02
Drugs
piperacillin + tazobactamcefazolin
03
Conditions
burn injury
Beyond the preview
Go deeper on 2019-002396-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002396-34.